A campaign of "communication for behavioural impact" to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage.
Identifieur interne : 007C52 ( Main/Merge ); précédent : 007C51; suivant : 007C53A campaign of "communication for behavioural impact" to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage.
Auteurs : K D Ramaiah [Inde] ; K N Vijay Kumar ; E. Hosein ; P. Krishnamoorthy ; D J Augustin ; K S Snehalatha ; B. Nanda ; P K DasSource :
- Annals of tropical medicine and parasitology [ 0003-4983 ] ; 2006.
Descripteurs français
- KwdFr :
- Attitude envers la santé, Communication, Connaissances, attitudes et pratiques en santé, Diéthylcarbamazine (usage thérapeutique), Filaricides (usage thérapeutique), Filariose lymphatique (), Filariose lymphatique (psychologie), Filariose lymphatique (traitement médicamenteux), Humains, Inde (épidémiologie), Maladies endémiques (), Observance thérapeutique (psychologie), Promotion de la santé (), Santé en zone urbaine, Santé en zone rurale, Éducation pour la santé (), Éducation pour la santé (organisation et administration).
- MESH :
- organisation et administration : Éducation pour la santé.
- psychologie : Filariose lymphatique, Observance thérapeutique.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Diéthylcarbamazine, Filaricides.
- épidémiologie : Inde.
- Attitude envers la santé, Communication, Connaissances, attitudes et pratiques en santé, Filariose lymphatique, Humains, Maladies endémiques, Promotion de la santé, Santé en zone urbaine, Santé en zone rurale, Éducation pour la santé.
- Wicri :
- geographic : Inde.
English descriptors
- KwdEn :
- Attitude to Health, Communication, Diethylcarbamazine (therapeutic use), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (prevention & control), Elephantiasis, Filarial (psychology), Endemic Diseases (prevention & control), Filaricides (therapeutic use), Health Education (methods), Health Education (organization & administration), Health Knowledge, Attitudes, Practice, Health Promotion (methods), Humans, India (epidemiology), Patient Compliance (psychology), Rural Health, Urban Health.
- MESH :
- chemical , therapeutic use : Diethylcarbamazine, Filaricides.
- geographic , epidemiology : India.
- drug therapy : Elephantiasis, Filarial.
- methods : Health Education, Health Promotion.
- organization & administration : Health Education.
- prevention & control : Elephantiasis, Filarial, Endemic Diseases.
- psychology : Elephantiasis, Filarial, Patient Compliance.
- Attitude to Health, Communication, Health Knowledge, Attitudes, Practice, Humans, Rural Health, Urban Health.
Abstract
In the mass drug administrations (MDA) that form the principal strategy of the Global Programme to Eliminate Lymphatic Filariasis, treatment coverages of at least 65%-80% will be needed if the programme is to be successful. In the Indian state of Tamil Nadu, where treatment coverages were typically <65%, a comprehensive strategy of advocacy and communication, called the "communication for behavioural impact" (COMBI) campaign, has been developed and implemented, in an attempt to improve treatment coverage. This strategy combined advocacy, aimed at state-, district- and village-level administrations, with communication activities targeted at individual communities. The main aim was to alter the behaviour of many of those included in the rounds of MDA, so that they would be more likely to accept and consume the diethylcarbamazine tablets offered to them. The COMBI campaign had two variants, COMBI(+) and the more intensive COMBI(+ +), each of which has been implemented in six districts. Both the variants included the "personal selling" of treatment, via door-to-door visiting by a total of 113,500 filaria-prevention assistants. These assistants were able to visit 34%-49% of the households in each target community. In the COMBI(+ +) districts, up to 44% and 38% of households received information on lymphatic filariasis and its elimination via television commercials and posters, respectively. Overall, 78% of the villages in the COMBI(+ +) districts and 33% of those in the COMBI(+) districts were considered to have had good exposure to the communication campaign. At the end of this campaign about 30% more people (than pre-campaign) believed that lymphatic filariasis could be eliminated and many of those targeted considered lymphatic filariasis to be a dreadful disease, knew that a particular day had been designated "Filaria Day", and thought that the tablets offered in MDA should be consumed to prevent or eliminate the disease. Apparently as the result of the COMBI campaign, drug consumption increased, from 33% of those living in endemic communities, to 37% in the COMBI(+) districts and to 49% in the COMBI(+ +). Coverages as high as 65%-73% were recorded among those who had had the maximum exposure to the communication campaign. These results indicate that the COMBI campaign favourably changed the perception and behaviour of the people towards the elimination of lymphatic filariasis. The costs of the COMBI(+) and COMBI(+ +) strategies were only U.S.$0.002 and U.S.$0.009 per capita, respectively.
DOI: 10.1179/136485906X105598
PubMed: 16762115
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003967
- to stream PubMed, to step Curation: 003967
- to stream PubMed, to step Checkpoint: 003967
- to stream Ncbi, to step Merge: 002292
- to stream Ncbi, to step Curation: 002292
- to stream Ncbi, to step Checkpoint: 002292
Links to Exploration step
pubmed:16762115Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A campaign of "communication for behavioural impact" to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage.</title>
<author><name sortKey="Ramaiah, K D" sort="Ramaiah, K D" uniqKey="Ramaiah K" first="K D" last="Ramaiah">K D Ramaiah</name>
<affiliation wicri:level="1"><nlm:affiliation>Vector Control Research Centre (Indian Council of Medical Research), Medical Complex, Indira Nagar, Pondicherry-605 006, India. ramaiahk@yahoo.com</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Vector Control Research Centre (Indian Council of Medical Research), Medical Complex, Indira Nagar, Pondicherry-605 006</wicri:regionArea>
<wicri:noRegion>Pondicherry-605 006</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vijay Kumar, K N" sort="Vijay Kumar, K N" uniqKey="Vijay Kumar K" first="K N" last="Vijay Kumar">K N Vijay Kumar</name>
</author>
<author><name sortKey="Hosein, E" sort="Hosein, E" uniqKey="Hosein E" first="E" last="Hosein">E. Hosein</name>
</author>
<author><name sortKey="Krishnamoorthy, P" sort="Krishnamoorthy, P" uniqKey="Krishnamoorthy P" first="P" last="Krishnamoorthy">P. Krishnamoorthy</name>
</author>
<author><name sortKey="Augustin, D J" sort="Augustin, D J" uniqKey="Augustin D" first="D J" last="Augustin">D J Augustin</name>
</author>
<author><name sortKey="Snehalatha, K S" sort="Snehalatha, K S" uniqKey="Snehalatha K" first="K S" last="Snehalatha">K S Snehalatha</name>
</author>
<author><name sortKey="Nanda, B" sort="Nanda, B" uniqKey="Nanda B" first="B" last="Nanda">B. Nanda</name>
</author>
<author><name sortKey="Das, P K" sort="Das, P K" uniqKey="Das P" first="P K" last="Das">P K Das</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16762115</idno>
<idno type="pmid">16762115</idno>
<idno type="doi">10.1179/136485906X105598</idno>
<idno type="wicri:Area/PubMed/Corpus">003967</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003967</idno>
<idno type="wicri:Area/PubMed/Curation">003967</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003967</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003967</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003967</idno>
<idno type="wicri:Area/Ncbi/Merge">002292</idno>
<idno type="wicri:Area/Ncbi/Curation">002292</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002292</idno>
<idno type="wicri:doubleKey">0003-4983:2006:Ramaiah K:a:campaign:of</idno>
<idno type="wicri:Area/Main/Merge">007C52</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A campaign of "communication for behavioural impact" to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage.</title>
<author><name sortKey="Ramaiah, K D" sort="Ramaiah, K D" uniqKey="Ramaiah K" first="K D" last="Ramaiah">K D Ramaiah</name>
<affiliation wicri:level="1"><nlm:affiliation>Vector Control Research Centre (Indian Council of Medical Research), Medical Complex, Indira Nagar, Pondicherry-605 006, India. ramaiahk@yahoo.com</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Vector Control Research Centre (Indian Council of Medical Research), Medical Complex, Indira Nagar, Pondicherry-605 006</wicri:regionArea>
<wicri:noRegion>Pondicherry-605 006</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vijay Kumar, K N" sort="Vijay Kumar, K N" uniqKey="Vijay Kumar K" first="K N" last="Vijay Kumar">K N Vijay Kumar</name>
</author>
<author><name sortKey="Hosein, E" sort="Hosein, E" uniqKey="Hosein E" first="E" last="Hosein">E. Hosein</name>
</author>
<author><name sortKey="Krishnamoorthy, P" sort="Krishnamoorthy, P" uniqKey="Krishnamoorthy P" first="P" last="Krishnamoorthy">P. Krishnamoorthy</name>
</author>
<author><name sortKey="Augustin, D J" sort="Augustin, D J" uniqKey="Augustin D" first="D J" last="Augustin">D J Augustin</name>
</author>
<author><name sortKey="Snehalatha, K S" sort="Snehalatha, K S" uniqKey="Snehalatha K" first="K S" last="Snehalatha">K S Snehalatha</name>
</author>
<author><name sortKey="Nanda, B" sort="Nanda, B" uniqKey="Nanda B" first="B" last="Nanda">B. Nanda</name>
</author>
<author><name sortKey="Das, P K" sort="Das, P K" uniqKey="Das P" first="P K" last="Das">P K Das</name>
</author>
</analytic>
<series><title level="j">Annals of tropical medicine and parasitology</title>
<idno type="ISSN">0003-4983</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Attitude to Health</term>
<term>Communication</term>
<term>Diethylcarbamazine (therapeutic use)</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Elephantiasis, Filarial (prevention & control)</term>
<term>Elephantiasis, Filarial (psychology)</term>
<term>Endemic Diseases (prevention & control)</term>
<term>Filaricides (therapeutic use)</term>
<term>Health Education (methods)</term>
<term>Health Education (organization & administration)</term>
<term>Health Knowledge, Attitudes, Practice</term>
<term>Health Promotion (methods)</term>
<term>Humans</term>
<term>India (epidemiology)</term>
<term>Patient Compliance (psychology)</term>
<term>Rural Health</term>
<term>Urban Health</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Attitude envers la santé</term>
<term>Communication</term>
<term>Connaissances, attitudes et pratiques en santé</term>
<term>Diéthylcarbamazine (usage thérapeutique)</term>
<term>Filaricides (usage thérapeutique)</term>
<term>Filariose lymphatique ()</term>
<term>Filariose lymphatique (psychologie)</term>
<term>Filariose lymphatique (traitement médicamenteux)</term>
<term>Humains</term>
<term>Inde (épidémiologie)</term>
<term>Maladies endémiques ()</term>
<term>Observance thérapeutique (psychologie)</term>
<term>Promotion de la santé ()</term>
<term>Santé en zone urbaine</term>
<term>Santé en zone rurale</term>
<term>Éducation pour la santé ()</term>
<term>Éducation pour la santé (organisation et administration)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diethylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>India</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Health Education</term>
<term>Health Promotion</term>
</keywords>
<keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Éducation pour la santé</term>
</keywords>
<keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Health Education</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term>
<term>Endemic Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Filariose lymphatique</term>
<term>Observance thérapeutique</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Elephantiasis, Filarial</term>
<term>Patient Compliance</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Diéthylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Inde</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Attitude to Health</term>
<term>Communication</term>
<term>Health Knowledge, Attitudes, Practice</term>
<term>Humans</term>
<term>Rural Health</term>
<term>Urban Health</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Attitude envers la santé</term>
<term>Communication</term>
<term>Connaissances, attitudes et pratiques en santé</term>
<term>Filariose lymphatique</term>
<term>Humains</term>
<term>Maladies endémiques</term>
<term>Promotion de la santé</term>
<term>Santé en zone urbaine</term>
<term>Santé en zone rurale</term>
<term>Éducation pour la santé</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Inde</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the mass drug administrations (MDA) that form the principal strategy of the Global Programme to Eliminate Lymphatic Filariasis, treatment coverages of at least 65%-80% will be needed if the programme is to be successful. In the Indian state of Tamil Nadu, where treatment coverages were typically <65%, a comprehensive strategy of advocacy and communication, called the "communication for behavioural impact" (COMBI) campaign, has been developed and implemented, in an attempt to improve treatment coverage. This strategy combined advocacy, aimed at state-, district- and village-level administrations, with communication activities targeted at individual communities. The main aim was to alter the behaviour of many of those included in the rounds of MDA, so that they would be more likely to accept and consume the diethylcarbamazine tablets offered to them. The COMBI campaign had two variants, COMBI(+) and the more intensive COMBI(+ +), each of which has been implemented in six districts. Both the variants included the "personal selling" of treatment, via door-to-door visiting by a total of 113,500 filaria-prevention assistants. These assistants were able to visit 34%-49% of the households in each target community. In the COMBI(+ +) districts, up to 44% and 38% of households received information on lymphatic filariasis and its elimination via television commercials and posters, respectively. Overall, 78% of the villages in the COMBI(+ +) districts and 33% of those in the COMBI(+) districts were considered to have had good exposure to the communication campaign. At the end of this campaign about 30% more people (than pre-campaign) believed that lymphatic filariasis could be eliminated and many of those targeted considered lymphatic filariasis to be a dreadful disease, knew that a particular day had been designated "Filaria Day", and thought that the tablets offered in MDA should be consumed to prevent or eliminate the disease. Apparently as the result of the COMBI campaign, drug consumption increased, from 33% of those living in endemic communities, to 37% in the COMBI(+) districts and to 49% in the COMBI(+ +). Coverages as high as 65%-73% were recorded among those who had had the maximum exposure to the communication campaign. These results indicate that the COMBI campaign favourably changed the perception and behaviour of the people towards the elimination of lymphatic filariasis. The costs of the COMBI(+) and COMBI(+ +) strategies were only U.S.$0.002 and U.S.$0.009 per capita, respectively.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007C52 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 007C52 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Main |étape= Merge |type= RBID |clé= pubmed:16762115 |texte= A campaign of "communication for behavioural impact" to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:16762115" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |